| Periodo | Debito a lungo term. | Var. |
| 2025 | 0 USD | -100.00% |
| 2024 | 25.00 M USD | -16.67% |
| 2023 | 30.00 M USD | +0.00% |
| 2022 | 30.00 M USD | — |
| 2021 | 0 USD | -100.00% |
| 2020 | 2.41 M USD | — |
Rani Therapeutics Holdings Inc. is a pioneering entity in the biopharmaceutical field, dedicated to transforming the delivery of biologics and other macromolecules. The company endeavors to address challenges associated with the oral administration of biologic drugs, which are typically delivered through injections, by developing the RaniPill capsule. This innovative technology is designed to enable the oral delivery of these complex drugs, significantly impacting how treatments can be administered for chronic diseases such as diabetes, rheumatoid arthritis, and other autoimmune disorders. Operating at the intersection of pharmaceuticals and cutting-edge medical technology, Rani Therapeutics stands as a disruptive force within the healthcare sector, aiming to enhance patient compliance and expand market access for critical therapies. Established to advance healthcare delivery, the company's work holds potential significance for pharmaceutical manufacturers, healthcare providers, and patients, offering a unique solution to a long-standing challenge in the medical industry. As Rani Therapeutics Holdings Inc. continues its pursuit of novel drug delivery methods, it remains an important player in the biopharmaceutical innovation landscape.